Skip to main content
SpringerLink
Log in

Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors

  • original report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Stereotactic body radiotherapy (SBRT) delivers precise concentric radiation to a tumor. It is well established that local control depends on the biologically effective dose (BED) delivered, with BED10 of ≥100 as a significant predictor of local control. The aim of this study was to evaluate factors associated with overall survival (OS) in inoperable lung cancer cases treated with SBRT. From 2013 to 2016, 22 patients with inoperable lung cancer treated with SBRT who could be followed up until their time of death were retrospectively enrolled. Data on sex, age, dose (Gray), number of fractions, BED (α/β = 10), pathology, tumor location, performance status, and background lung disease were collected. The median total dose at the isocenter was 50 Gy, and median BED was 120 Gy. OS was compared in groups with BED of ≥120 Gy (“high-BED”; n = 15) and BED of <120 Gy (“low-BED,” n = 7). Overall, 1‑year OS was 48%. In the univariate analysis, the number of fractions, BED, and pathology were significantly associated with OS. The high-BED group showed better OS, with 1‑ and 2‑year OS of 64% and 21%, respectively, compared with 25% and 0%, respectively, for the low-BED group (p = 0.04). No adverse event of grade 3 or higher occurred. For these inoperable lung cancer cases treated with SBRT, BED was significantly associated with OS. The poor OS rate observed in this case series might be associated with the fact that all the tumors were inoperable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–107. https://doi.org/10.1001/jama.2010.261.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yu JB, Soulos PR, Cramer LD, Decker RH, Kim AW, Gross CP. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer. 2015;121:2341–9. https://doi.org/10.1002/cncr.29359.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112:250–5. https://doi.org/10.1016/j.radonc.2014.08.031.

    Article  PubMed  Google Scholar 

  4. Roesch J, Panje C, Sterzing F, Mantel F, Nestle U, Andratschke N, et al. SBRT for centrally localized NSCLC—what is too central? Radiat Oncol. 2016;11:157.

    Article  CAS  Google Scholar 

  5. Videtic GM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7:295–301.

    Article  Google Scholar 

  6. Chua KLM, Sin I, Fong KW, Chua MLK, Onishi H. Stereotactic body radiotherapy for early stage lung cancer-historical developments and future strategies. Chin Clin Oncol. 2017;6:S20. https://doi.org/10.21037/cco.2017.08.02.

    Article  PubMed  Google Scholar 

  7. Lu C, Lei Z, Wu H, Lu H. Evaluating risk factors of radiation pneumonitis after stereotactic body radiation therapy in lung tumor: Meta-analysis of 9 observational studies. PLoS ONE. 2018;13(2018):e208637. https://doi.org/10.1371/journal.pone.0208637.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Onishi H, Araki T, Shirato H. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer. 2004;101:1623–31. https://doi.org/10.1002/cncr.20539.

    Article  PubMed  Google Scholar 

  9. Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93:989–96. https://doi.org/10.1016/j.ijrobp.2015.07.2278.

    Article  PubMed  Google Scholar 

  10. Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;91:344–50. https://doi.org/10.1016/j.ijrobp.2014.10.002.

    Article  PubMed  Google Scholar 

  11. Eriguchi T, Takeda A, Sanuki N, Nishimura S, Takagawa Y, Enomoto T, et al. Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer. J Radiat Res. 2016;57:265–72. https://doi.org/10.1093/jrr/rrw023.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Navarro-Martin A, Aso S, Cacicedo J, Arnaiz M, Navarro V, Rosales S, et al. Phase II Trial of SBRT for Stage I NSCLC: survival, local control, and lung function at 36 Months. J Thorac Oncol. 2016;11:1101–11. https://doi.org/10.1016/j.jtho.2016.03.021.

    Article  PubMed  Google Scholar 

  13. Oshiro Y, Aruga T, Tsuboi K, Marino K, Hara R, Sanayama Y, et al. Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol. 2010;186:274–9.

    Article  Google Scholar 

  14. Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys. 2010;77:1146–50.

    Article  Google Scholar 

  15. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012;7:1394–9.

    Article  Google Scholar 

  16. Milano MT, Chen Y, Katz AW, Philip A, Schell MC, Okunieff P. Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol. 2009;91:301–6.

    Article  Google Scholar 

  17. Andratschke N, Zimmermann F, Boehm E, Schill S, Schoenknecht C, Thamm R, et al. Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol. 2011;101:245–9.

    Article  Google Scholar 

  18. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Asahi University Hospital, 3–23 Hashimoto-cho. Gifu city, 500-8523, Gifu, Japan

    Osamu Tanaka M.D, Takuya Taniguchi M.P. & Kousei Ono M.P.

  2. Department of Respiratory Medicine, Asahi University Hospital, 3–23 Hashimoto-cho. Gifu city, 500-8523, Gifu, Japan

    Norihiko Funaguchi M.D. & Sayaka Toyoshi M.D.

  3. Department of Radiology, Gifu University Hospital, 1–1 Yanagido, Gifu city, 501-1194, Gifu, Japan

    Chiyoko Makita M.D. & Masayuki Matsuo M.D.

Authors
  1. Osamu Tanaka M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norihiko Funaguchi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sayaka Toyoshi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuya Taniguchi M.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kousei Ono M.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chiyoko Makita M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masayuki Matsuo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osamu Tanaka M.D.

Ethics declarations

Conflict of interest

O. Tanaka, N. Funaguchi, S. Toyoshi, T. Taniguchi, K. Ono, C. Makita, and M. Matsuo declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

National Clinical Trial number: UMIN000034389

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanaka, O., Funaguchi, N., Toyoshi, S. et al. Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors. memo 13, 353–356 (2020). https://doi.org/10.1007/s12254-020-00617-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-020-00617-w

Keywords

Search

Navigation